Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Capital Expenditures: 2012-2024

Historic Capital Expenditures for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $1.3 million.

  • Ocular Therapeutix's Capital Expenditures rose 6633.71% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 506.67%. This contributed to the annual value of $1.3 million for FY2024, which is 78.84% down from last year.
  • As of FY2024, Ocular Therapeutix's Capital Expenditures stood at $1.3 million, which was down 78.84% from $6.1 million recorded in FY2023.
  • Ocular Therapeutix's Capital Expenditures' 5-year high stood at $6.1 million during FY2023, with a 5-year trough of $841,000 in FY2020.
  • For the 3-year period, Ocular Therapeutix's Capital Expenditures averaged around $3.7 million, with its median value being $3.7 million (2022).
  • As far as peak fluctuations go, Ocular Therapeutix's Capital Expenditures spiked by 211.14% in 2022, and later tumbled by 78.84% in 2024.
  • Yearly analysis of 5 years shows Ocular Therapeutix's Capital Expenditures stood at $841,000 in 2020, then soared by 41.97% to $1.2 million in 2021, then soared by 211.14% to $3.7 million in 2022, then surged by 63.85% to $6.1 million in 2023, then crashed by 78.84% to $1.3 million in 2024.